{"name":"Acadia Pharmaceuticals","slug":"acadia","ticker":"ACAD","exchange":"NASDAQ","domain":"acadia-pharm.com","description":"Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.","hq":"San Diego, CA","founded":0,"employees":"796","ceo":"Catherine Owen Adams","sector":"CNS / Rare Disease","stockPrice":22.07,"stockChange":-0.11,"stockChangePercent":-0.5,"marketCap":"$3.8B","metrics":{"revenue":1095250048,"revenueGrowth":9.7,"grossMargin":61.6,"rdSpend":328802000,"netIncome":391000000,"cash":851457984,"dividendYield":0,"peRatio":10,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Nuplazid patent cliff ($341.8M at risk)","drug":"Nuplazid","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ACP-211","genericName":"ACP-211","slug":"acp-211","indication":"Treatment of excessive daytime sleepiness in patients with narcolepsy","status":"phase_2"},{"name":"ACP-104","genericName":"ACP-104","slug":"acp-104","indication":"Excessive daytime sleepiness in patients with narcolepsy or other conditions","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ACP-204","genericName":"ACP-204","slug":"acp-204","indication":"Cognitive impairment associated with schizophrenia","status":"phase_3"}]}],"pipeline":[{"name":"ACP-211","genericName":"ACP-211","slug":"acp-211","phase":"phase_2","mechanism":"ACP-211 is a selective histamine H3 receptor inverse agonist.","indications":["Treatment of excessive daytime sleepiness in patients with narcolepsy"],"catalyst":""},{"name":"ACP-104","genericName":"ACP-104","slug":"acp-104","phase":"phase_2","mechanism":"ACP-104 is a selective histamine H3 receptor inverse agonist.","indications":["Excessive daytime sleepiness in patients with narcolepsy or other conditions"],"catalyst":""},{"name":"ACP-204","genericName":"ACP-204","slug":"acp-204","phase":"phase_3","mechanism":"ACP-204 is a muscarinic M1 receptor agonist that enhances cholinergic neurotransmission to improve cognitive and psychiatric symptoms.","indications":["Cognitive impairment associated with schizophrenia","Negative symptoms of schizophrenia","Psychosis in Alzheimer's disease"],"catalyst":""}],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Acadia Pharmaceuticals reported its fourth quarter and full year 2022 financial results, with net sales of $341.8 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2022-10-31","type":"deal","headline":"Acadia Pharmaceuticals Announces Collaboration with the Michael J. Fox Foundation for Parkinson's Research","summary":"Acadia Pharmaceuticals announced a collaboration with the Michael J. Fox Foundation for Parkinson's Research to advance the development of treatments for Parkinson's disease.","drugName":"","sentiment":"positive"},{"date":"2022-08-01","type":"regulatory","headline":"FDA Approves Trofinetide for the Treatment of Rett Syndrome","summary":"The FDA approved Trofinetide (trofinetide) for the treatment of Rett syndrome, a rare genetic disorder.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOM3U4R093bkR4SDRyM3F1UU1FZkR6NzJQWVVvNHJIMEZ4RlZkQnZWZVZOSVZfVFE2YkJiUnRlbm9JZE9yd2NZWjMza0xrMmtaYTBvVlFIUXFibGtTMWNTTkVGbjZHZGhKSWNWTHowVlpEQ0Zia0FfUDE1aGlsS04yQWJzT29xeXRNOGk5YVlMTlVrM09L?oc=5","date":"2026-03-25","type":"pipeline","source":"Seeking Alpha","summary":"Acadia Pharma upgraded at BofA following stock pullback - Seeking Alpha","headline":"Acadia Pharma upgraded at BofA following stock pullback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPc2Y0b3VXQkJScUo0RTU1bG5vWDZfT2dNdFhDcXhiZTdZVGlVR1BScEtBZVdaMFhJcDBGR1FuWEJTTDJBTzFocDdZdk0zSXU3d19OT1lJNkxfc2ZMc3RvdG9hVllqaU9CaTlKS2ljdmFRcUJfbTM4WUQ0bzBBUUFFZWRsX2VZREpoYWdTTE9fRTc4QWlZWEs4d2JBMUJmSFRLX3NzTkMyS0Q3bm5ScFl1OGk5UmpxbGxXTHJLZlR0RTI?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"Watch Acadia’s fireside chat at Stifel’s 2026 Virtual CNS Forum - Stock Titan","headline":"Watch Acadia’s fireside chat at Stifel’s 2026 Virtual CNS Forum","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxON2VCQXQ3NERfNFpHX1NzNWxDTWQtRmJucG82eTUtMmxWMnM1aFJiR2xJWG9OOURzZmt3QzM5dHp0S05Rekw3S2syTF9FTjQxVk5Nek1TV1ZXYlpzWDBQOXh2UVBEOGxlbDB0V01CVU9NeFJkWkVOZDc5Rm9RaDZ0UGdYN1JhVVJoWkVHOFoyVktYLXdLdWd4NVlJQ2w4ZUF6NVphNEJhRDBUSDFVSG5ROEtUU3ZoQWN4X1FZ?oc=5","date":"2026-03-03","type":"pipeline","source":"Stock Titan","summary":"Vertex senior finance leader Jonathan Poole joins Acadia Pharma board - Stock Titan","headline":"Vertex senior finance leader Jonathan Poole joins Acadia Pharma board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPSHJ0eXJETzdiWWY0cld1S0tXRU9jVXgycS0td2dxWTNjbEtVX3NsWWxlMGR3T1ZKYlJPaGtYdkRFTlhWYTFRLV9lemUzZUJHVXVhQm9HOFN2Q2cya3FnZ3RSbUtsd0JZMnZiYUMxc291eXUwWUQ1MVRyd1J1OGpUOWVtMjFoZlNhRWxxbXB5QWFpenA0bUJHOS1GRWU1cm9MU0JQX21BWGJFTGNIZHBiMlVlN19QNFVDNVE?oc=5","date":"2026-03-02","type":"pipeline","source":"Stock Titan","summary":"EU advisers reject Rett syndrome drug, maker pushes for second review - Stock Titan","headline":"EU advisers reject Rett syndrome drug, maker pushes for second review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNM24yUno3Nmo4LVpkUkNSaUdHZWVsVXFTa3c4NVc2MVl5YWk3cWhEVGNVYllHVG52M3I1LTFZcWhBR0wwbG13bXprMW9DeUVkcXNrXzhiWnJUbDRfT2ZrUkI1aE9PV2paTGRrVGdGSU8tYkZJVzdxdkZsaHAzc3NZdVBSa0VOSkRIcjROWTh4WTV2YUJ4Q0xXOFlmS1hKd1BMekpwZE9kRnZwc1NSZ0xVTEI3d2k4T0Q5V3AtdVEzVzZiWHhCS3M2UUJQbkpyakxIelFCcGl3dw?oc=5","date":"2026-02-28","type":"regulatory","source":"Seeking Alpha","summary":"Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker - Seeking Alpha","headline":"Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker","sentiment":"positive"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNTWpSZXlsaTlWTlNwTFVUZWhqUGNCVXhnbkVoYnBtaExsTVVDRW54a1ZIX2pWaEJCeDdhdHFQRkQ4bHdOWUZmdlBmUDU1LU55RDRqUjhVUndxajd4RkplYzQ5dGIyX2ZOd2tJU3FuaUljZUxZUzVJd2NKMHFoZGx4OXRzMkllZ3dmLVZGczJ3dHRCbU96TDlDb0F3SWhrUEJCNXhzalVqb2RSaktJM0xwNHEwMXhfX2c?oc=5","date":"2026-02-21","type":"pipeline","source":"AD HOC NEWS","summary":"ACADIA Pharma Stock: What Wall Street Missed in the Latest Drop - AD HOC NEWS","headline":"ACADIA Pharma Stock: What Wall Street Missed in the Latest Drop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQMWc3TFFibFh0T29BWU01YVJLS01CeG40blhIWUF2UzBGN1Y2VlVkODVuSjlhMlFVUUZxRTlhVTZaTEo3XzhQYzk5OWtiNXctZXhidEZiSmNjVlc2dGtSZ3JTdjBOUGtXYUdHb2J6ZWtKb1paeU1aWDRMR01GOUZnLW5jQ0gxd2dZRkZSanFnOGo0VFFyWUVKVElBR3RsUFdEZFlwWjR1c2F2U2ZIWGJmN0hnVGRGc3I5Y0UzUXpjNUY0OGZLNFZZM0Y4WXM1dVV4ZUZRTTg0OFVwUm1KYnlFcjdLaDNnZlFycktOdUYyX0l1eFVHcGc?oc=5","date":"2026-02-04","type":"earnings","source":"Business Wire","summary":"Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Business Wire","headline":"Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOQ1J4c2ZjcGtWcHBpR0xLckljLWF3eFpDRVBQV3RDbUVIbjdCMXBZelQ3U2x3c0FPMmdrX1VueC1TUFNTbXZNbU4xdTBwaFptT3hGaHJoU1ktV1dWMWhmeC15T29UWXZPaEJFRGI0cTlic0tUbFZwYUZjM3Q5WkpNaEJiYTlTbHY3bEU1X2FTMEtELTNESFVXQlRrX0paWEJacU5RWUZ2ejBIVGo4M2FoVUxvTmNZRlhIRF9kTw?oc=5","date":"2026-02-03","type":"earnings","source":"TradingView","summary":"5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView","headline":"5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNLXJ1REQxQWtscDdzY3FHMEtQcFZpaW9DZHU5dWxBeVFwYTB4RmJJX2gtbmNzemtaTURJWU5RUGY4b1lrdnZ5aTFyWjVwMG54SUxxZlpmQlJxTVRpS3BvWk1NckVLM0RkeUhiQUE4d2t3eHk1U0F6bjFpMHpaM3plbUVrRndjUjgtSkhOVC14S2dfYTBXZE9oclpXTGZ1bXhwTTBlOXVXZ0NZTDRJLVA0Ni0xanJJVFVpMWpGYmJKR0JoMjB0SFNrVHp5OUlhSTlkY3NrZmY3VE5zUk1FZEhHZA?oc=5","date":"2025-10-15","type":"earnings","source":"Business Wire","summary":"Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 - Business Wire","headline":"Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPc1J3eUUtV1JWM1RDWXNzY2Q5dXNiT0pHc1FUZDc5V2JYSVNiTHhNU3VCVUszZlprV3BHbXl5c01nY0R1MTl5VXZRNVljdEh2Vi1oLUtuX0NHekRrOUM4SWFZRFM1NGJfSWROc0pWdDZqN0dDWGI3NGFoUkdtY1VrbWVPSXB1Ylda?oc=5","date":"2025-09-24","type":"pipeline","source":"Investor's Business Daily","summary":"Biotech Stocks Diverge As Genetic Disease Drug Fails - Investor's Business Daily","headline":"Biotech Stocks Diverge As Genetic Disease Drug Fails - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNMThHUTZmTVllSi1BWGlkRzQzNUt4TWFuMUhVOEdrTXRoX1lDRkp4Y3BlN01uNFQ3NzNVOHpKdGQ5bEJ3YjJTWFY2LVowb3kxX29fRGNsd2ZhVzRlUzZaN0hJaXFHRlRjTHltQ1dfV29JN2xqaEJBNXRHTGVRTEQwTkR2X3NrUXVZZ2JaeQ?oc=5","date":"2025-09-24","type":"pipeline","source":"Yahoo Finance","summary":"Lithium Americas, Oracle, Acadia Pharma: Trending Tickers - Yahoo Finance","headline":"Lithium Americas, Oracle, Acadia Pharma: Trending Tickers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOZmJxTkhrcGx0aXRmemxyd0R1dVA4dlVOTW1oUVVrZ0Q1elpOelpxeEdEampWdXZSZ0pTVG12WHZOY1BYdWk0Mk4tQ1M4d1E0UloxSnh4TkJzRUhDM0xRajU4bFNTaDlNUDdlVEMzbEpHY0ZBRFlZSE15NGZJNzZ3UjRYRHFkRkVxd1FXeU11dVNIb0tH?oc=5","date":"2025-08-27","type":"pipeline","source":"Yahoo Finance","summary":"How Investors May Respond To ACADIA Pharmaceuticals (ACAD) Hiring an Industry Veteran for Growth Strategy - Yahoo Finance","headline":"How Investors May Respond To ACADIA Pharmaceuticals (ACAD) Hiring an Industry Veteran for Growth Strategy","sentiment":"neutral"}],"patents":[{"drugName":"Nuplazid","drugSlug":"pimavanserin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":341800000}],"drugCount":3,"phaseCounts":{"phase_2":2,"phase_3":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Merck & Co.","Johnson & Johnson","Biogen"],"therapeuticFocus":["Central Nervous System (CNS)","Rare Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":726437000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":726437000,"period":"2023-12-31"},{"value":231041000,"period":"2023-12-31"},{"value":211699000,"period":"2023-09-30"},{"value":165235000,"period":"2023-06-30"},{"value":118462000,"period":"2023-03-31"}],"grossProfit":982507000,"grossProfitHistory":[{"period":"2025-12-31","value":982507000},{"period":"2024-12-31","value":875956000},{"period":"2023-12-31","value":684799000},{"period":"2022-12-31","value":507069000}],"rdSpend":328802000,"rdSpendHistory":[{"period":"2025-12-31","value":328802000},{"period":"2024-12-31","value":303249000},{"period":"2023-12-31","value":351619000},{"period":"2022-12-31","value":361575000}],"sgaSpend":548894000,"operatingIncome":104811000,"operatingIncomeHistory":[{"period":"2025-12-31","value":104811000},{"period":"2024-12-31","value":84279000},{"period":"2023-12-31","value":-73379000},{"period":"2022-12-31","value":-223596000}],"netIncome":391000000,"netIncomeHistory":[{"period":"2025-12-31","value":391000000},{"period":"2024-12-31","value":226451000},{"period":"2023-12-31","value":-61286000},{"period":"2022-12-31","value":-215975000}],"eps":2.3,"epsHistory":[{"period":"2025-12-31","value":2.3},{"period":"2024-12-31","value":1.36},{"period":"2023-12-31","value":-0.37},{"period":"2022-12-31","value":-1.34}],"cash":177695000,"cashHistory":[{"period":"2025-12-31","value":177695000},{"period":"2024-12-31","value":319589000},{"period":"2023-12-31","value":188657000},{"period":"2022-12-31","value":114846000}],"totalAssets":1564195000,"totalLiabilities":336805000,"totalDebt":52187000,"equity":1227390000,"operatingCashflow":109836000,"operatingCashflowHistory":[{"period":"2025-12-31","value":109836000},{"period":"2024-12-31","value":157719000},{"period":"2023-12-31","value":16702000},{"period":"2022-12-31","value":-114035000}],"capex":-4690000,"capexHistory":[{"period":"2025-12-31","value":-4690000},{"period":"2024-12-31","value":-523000},{"period":"2023-12-31","value":-50000},{"period":"2021-12-31","value":-1122000}],"freeCashflow":105146000,"dividendsPaid":null,"buybacks":null,"employees":796,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":155616000,"ebit":17391000,"ebitda":20315000,"period":"2025-12-31","revenue":283989000,"epsBasic":1.62,"netIncome":273568000,"rdExpense":84757000,"epsDiluted":1.6,"grossProfit":257764000,"operatingIncome":17391000},{"sga":133401000,"ebit":35756000,"ebitda":38706000,"period":"2025-09-30","revenue":278633000,"epsBasic":0.43,"netIncome":71779000,"rdExpense":87829000,"epsDiluted":0.42,"grossProfit":256986000,"operatingIncome":35756000},{"sga":133507000,"ebit":32374000,"ebitda":35309000,"period":"2025-06-30","revenue":264566000,"epsBasic":0.16,"netIncome":26666000,"rdExpense":77951000,"epsDiluted":0.16,"grossProfit":243832000,"operatingIncome":32374000},{"sga":126370000,"ebit":19290000,"ebitda":22241000,"period":"2025-03-31","revenue":244317000,"epsBasic":0.11,"netIncome":18987000,"rdExpense":78265000,"epsDiluted":0.11,"grossProfit":223925000,"operatingIncome":19290000},{"sga":130080000,"ebit":6988000,"ebitda":12202000,"period":"2024-12-31","revenue":259602000,"epsBasic":0.86,"netIncome":143742000,"rdExpense":100731000,"epsDiluted":0.86,"grossProfit":237799000,"operatingIncome":6988000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":22.07,"previousClose":22.18,"fiftyTwoWeekHigh":28.35,"fiftyTwoWeekLow":16.97,"fiftyTwoWeekRange":"16.97 - 28.35","fiftyDayAverage":21.87,"twoHundredDayAverage":23.72,"beta":0.86,"enterpriseValue":2997347584,"forwardPE":24.7,"priceToBook":3.06,"priceToSales":3.45,"enterpriseToRevenue":2.74,"enterpriseToEbitda":32.33,"pegRatio":0,"ebitda":92707000,"ebitdaMargin":8.5,"freeCashflow":154138624,"operatingCashflow":123494000,"totalDebt":50794000,"debtToEquity":4.1,"currentRatio":3.59,"returnOnAssets":3.7,"returnOnEquity":37.3,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":20,"targetMeanPrice":31.65,"targetHighPrice":45,"targetLowPrice":17,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.3,"institutionHeldPercent":101.4,"sharesOutstanding":171235870,"floatShares":127348117,"sharesShort":11156379,"shortRatio":6.43,"shortPercentOfFloat":6.5,"epsTrailing":2.21,"epsForward":0.89,"revenuePerShare":6.47,"bookValue":7.21,"officers":[{"age":55,"name":"Ms. Catherine E. Owen Adams","title":"CEO & Director"},{"age":51,"name":"Mr. Mark C. Schneyer","title":"Executive VP & CFO"},{"age":55,"name":"Ms. Jennifer J. Rhodes J.D.","title":"Executive VP, Chief Legal Officer & Secretary"},{"age":49,"name":"Dr. Elizabeth H. Z. Thompson Ph.D.","title":"Executive VP and Head of Research & Development"},{"age":49,"name":"Mr. Thomas Andrew Garner","title":"Executive VP & Chief Commercial Officer"},{"age":null,"name":"Mr. Scott  Cenci","title":"Senior VP, Chief Information & Data Officer"},{"age":null,"name":"Mr. Albert S. Kildani","title":"Senior Vice President of Investor Relations & Corporate Communications"}],"industry":"Biotechnology","irWebsite":"http://ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome","website":"https://www.acadia.com","phone":"858 558 2871"}}